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PURPOSE. Affecting children by age 3, primary congenital glaucoma (PCG) can cause debil-
itating vision loss by the developmental impairment of aqueous drainage resulting in high
intraocular pressure (IOP), globe enlargement, and optic neuropathy. TEK haploinsuffi-
ciency accounts for 5% of PCG in diverse populations, with low penetrance explained
by variable dysgenesis of Schlemm’s canal (SC) in mice. We report eight families with
TEK-related PCG, and provide evidence for SVEP1 as a disease modifier in family 8 with
a higher penetrance and severity.
METHODS. Exome sequencing identified coding/splice site variants with an allele
frequency less than 0.0001 (gnomAD). TEK variant effects were assayed in construct-
transfected HEK293 cells via detection of autophosphorylated (active) TEK protein. An
enucleated eye from an affected member of family 8 was examined via histology. SVEP1
expression in developing outflow tissues was detected by immunofluorescent staining of
7-day mouse anterior segments. SVEP1 stimulation of TEK expression in human umbilical
vascular endothelial cells (HUVECs) was measured by TaqMan quantitative PCR.
RESULTS. Heterozygous TEK loss-of-function alleles were identified in eight PCG families,
with parent–child disease transmission observed in two pedigrees. Family 8 exhibited
greater disease penetrance and severity, histology revealed absence of SC in one eye,
and SVEP1:p.R997C was identified in four of the five affected individuals. During SC
development, SVEP1 is secreted by surrounding tissues. SVEP1:p.R997C abrogates stim-
ulation of TEK expression by HUVECs.
CONCLUSIONS. We provide further evidence for PCG caused by TEK haploinsufficiency,
affirm autosomal dominant inheritance in two pedigrees, and propose SVEP1 as a modi-
fier of TEK expression during SC development, affecting disease penetrance and severity.
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Affecting children within the first 3 years of life, primarycongenital glaucoma (PCG, MIM: 231300) is potentially
a debilitating ocular disease with irreversible blindness.1,2
Elevated intraocular pressure (IOP) is the primary factor
for disease progression, causing multiple ocular structural
changes, such as globe enlargement (buphthalmos), corneal
stretching with thinning and edema, optic nerve damage
with characteristic cupping of the optic disc, and retinal
ganglion cell loss with concordant patterns of visual field
loss and blindness.2
In a healthy eye, the IOP is maintained via balanced
aqueous humor production in the ciliary body and drainage
through the conventional and uveoscleral outflow path-
ways.3,4 In humans, approximately 80% of aqueous humor
drains through the conventional egress pathway, which is
comprised of the trabecular meshwork (TM) and Schlemm’s
canal (SC), a unique hybrid vessel with both vascular
and lymphatic properties.5,6 PCG can result from develop-
mental defects in the conventional outflow pathway, lead-
ing to aqueous retention and subsequently increased IOP.
However, the underlying molecular cause of PCG remains
largely undiscovered, with deleterious variants in CYP1B1,
LTBP2, TEK, and ANGPT1 accounting for only 26% of
affected individuals from diverse populations.7–14
Heterozygous loss-of-function (LoF) variants in the tunica
interna endothelial cell kinase gene, TEK (or TIE2, MIM
600221), have been estimated to cause 5% of PCG in
diverse populations.13 The encoded cell membrane recep-
tor is expressed by vascular endothelial cells (ECs) and
its phosphorylation signaling is important for maintenance
of vascular homeostasis.15–19 High expression of Tek has
also been detected in the ECs of SC.6,20 In mice, homozy-
gous deletion of the Tek gene after heart formation (E16.5)
resulted in the developmental loss of SC, highly elevated IOP,
globe enlargement, optic nerve damage, retinal ganglion cell
degeneration and vision loss.21 Furthermore, mice hemizy-
gous for Tek develop a variably hypomorphic SC with convo-
lutions and focal narrowings, a hypoplastic TM, and an aver-
age 25% increase in IOP compared with control animals.13
Importantly, the variable IOP levels were correlated with
the degree of SC hypomorphism, thus providing an explana-
tion for the decreased penetrance and variable expressivity
observed in human families.13
We describe eight PCG families that harbor unreported
heterozygous LoF variants in TEK, including two noncon-
sanguineous families demonstrating direct parent-to-child
disease transmission over multiple generations. These find-
ings strongly support an autosomal dominant mode of inher-
itance in these instances. In one pedigree, four of the five
affected individuals harbored an additional rare variant in
the SVEP1 (Sushi, Von Willebrand factor type A, epider-
mal growth factor, and pentraxin domain containing-1) gene
FIGURE 1. Pedigrees of PCG families one through eight. Phenotypic presentations are shown for PCG (black shaded), juvenile open-
angle glaucoma (JOAG, dark grey shaded), primary open-angle glaucoma (POAG), (light grey shaded), and asymptomatic (unshaded). For
participating family members, the genotypes are given below each individual: heterozygous TEK variant, T; heterozygous SVEP1 variant,
S; reference genotype, +. Probands in multi-affected families are denoted by arrows. An ocular pathology sample was obtained from the
individual denoted by #.
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TABLE 1. Ocular Clinical Information for PCG Families 1 Through 8
Individual Glaucoma Onset age Cup–Disk Ratio Surgery/Treatments Other
F1-II1 PCG (OD) <1 yo 1.0 (PS) 3 angle surgeries Megalocornea (diameter 14 mm, 10 yo),
IOP 35 mm Hg (10 yo), 30 mm Hg
(PS)
F2-II1 PCG (OS) 3 months 0.1/0.3 (PS) Goniotomy (OS), trabeculectomies (2 OS) Haab striae, IOP 17 mm Hg (PS)
F3-II1 PCG (OU) <1 yo 0.3/0.3 (PS) 1 surgery (OU) IOP 21/22 mm Hg (PS)
F4-II1 PCG (OU) 4 months 0.2/0.2 (PS) Goniotomy, trabeculectomies (2 OS) Enlarged corneas (13.5/13 mm), corneal
edema with clouding, Haab striae,
IOP 19/22.5 mm Hg (PS), parents 1st
cousins once removed
F5-II1 PCG (OD) 4 months 0.8 (OD) Topical beta-blocker medication (timolol) Buphthalmos, IOP 15 mm Hg (with
timolol)
F6-II2 PCG Childhood
F6-II3 POAG 70s
F6-III1 POAG 50s
F6-III4 PCG 4 yo
F6-IV2 PCG (OU) 2 yo 0.8 (OD) Enucleation (OS), goniotomy (OU),
trabeculotomies (2 OS, 1 OD)
Scleral staphyloma (OS)
F6-V2 PCG (OU) 4 months 0.6/0.5 Tube shunt, diode cyclophotocoagulation
(OD)
Iris posterior synechiae (OD), scleral
staphyloma (OD)
F7-II1 PCG (OU) Birth
F8-I2 PCG (OU) <5 yo Enucleation (OU)
F8-II1 PCG (OU) Enucleation (OD) Posterior vitreous detachment
F8-III2 PCG (OU) 8 months 0.3 (OS) Trabeculectomies (OU), superior sector
iridectomy (OS), tube shunt (OD),
enucleation (OD, 24 yo)
OS, 38 yo: IOP 23 mm Hg, posterior
vitreous detachment, bleb epithelial
overgrowth (trabeculectomy),
cataract, visual acuity light perception
only
F8-IV2 PCG (OS) 4 yo Multiple goniotomies/trabeculectomies
(OS)
F8-IV3 PCG (OU) 3 months Multiple goniotomies/cyclocryotherapies
(OS), trabeculectomy (OS), double plate
Molteno implant (OS), Molteno implant
(OD), enucleation (OD), revision of
Molteno implant (OS)
IOP 30/30 mm Hg (10 yo), retinal
detachment (OD),ocular pathology
sample; moderate corneal band
keratopathy (OS), cataract with
posterior iris synechiae (OS),
Enlarged cornea (diameter 13 mm,
OS), visual acuity 20/400 (OS), IOP
10 mm Hg (OS, 28 yo) following
ciliary body destruction
F8-IV5 JOAG Astigmatism, strabismus, cornea
problems
F8-V3 PCG (OU) 18 months Goniotomy, multiple surgeries
PCG, primary congenital glaucoma; POAG, primary open-angle glaucoma; JOAG, juvenile open-angle glaucoma; OU, both eyes; OS, left
eye; OD, right eye; yo, years old; PS, post-surgery.
(MIM 611691), which we hypothesized may act as a modi-
fier of TEK expression, leading to a further decrease in TEK
signaling, and subsequent increased disease penetrance and
severity.
METHODS
Detailed materials and methods are given in the Supplemen-
tary Materials.
Study Participants
Studies involving human participants were approved by
the Ethical Committee of the Faculty of Medicine, Univer-
sity of Coimbra, Portugal; the Ethical Committee of the
Shahid Beheshti University of Medical Sciences, Iran; the
Southern Adelaide Clinical Human Research Ethics Commit-
tee, Australia; the National Institutes of Health Institu-
tional Review Board, Bethesda, Maryland; or the Health
Sciences Institutional Review Board at the University of
Wisconsin–Madison, Wisconsin. After an explanation of the
nature and possible consequences of the study, consent was
obtained, and individuals were enrolled.
Patients with PCG were referred by their pediatric
ophthalmologist. A clinical diagnosis was confirmed by age
of onset less than 3 years, increased IOP (>21 mm Hg),
abnormal corneal appearance (diameter >10.5 mm, pres-
ence of edema and/or Haab striae), and cupping of the optic
nerve head (>0.3 cup to disc ratio).
Exome Sequencing and Variant Filtering
Exome sequencing was performed at independent insti-
tutions as detailed in the Supplementary Materials. Rare
variants within exonic and splice site regions were eval-
uated for likely pathogenicity, including an assessment of
evolutionary conservation of the affected residue, in silico
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TABLE 2. TEK and SVEP1 Variants Identified in Eight PCG Families
Family ID Ethnicity Gene
Chromosome
Position Exon
Coding DNA
Variant
Protein
Alteration
Variant Count:
Total Allelesa
Variant Count:
ETHNICALLY
Matched Allelesb
1 European (Portugal) TEK 9:27169562 4 c.563T>G p.V188G 0 : 251,260 0 : 113,570
2 European (Australia) TEK 9:27212730 17 c.2712C>G p.Y904* 0 : 251,242 0 : 113,590
3 European (Australia) TEK 9:27218815 20 c.3103G>C p.G1035R 0 : 251,376 0 : 113,694
4 South Asian (Iran) TEK 9:27168535 3 c.407G>T p.G136V 0 : 251,176 0 : 30,610
5 South Asian (Iran) TEK 9:27172716 5 c.731C>G p.P244R 0 : 251,198 0 : 30,608
6 European (America) TEK 9:27169577 4 c.578A>G p.Y193C 0 : 251256 0 : 30,616
7 European (America) TEK 9:27192626 IVS11 c.1624+5G>A p.Val497_Ile541del 1 : 250,382 0 : 112,886
8 European (America) TEK 9:27206737 15 c.2522C>T p.A841V 1 : 251,142 1 : 113,500
SVEP1 9:113233653 16 c.2989C>T p.R997C 4 : 248,368 2 : 112,418
Chromosome position in accordance with GRCh37/hg19 assembly. TEK mRNA reference sequence NM_000459.4. TEK protein reference
sequence NP_000450.2. SVEP1 mRNA reference sequence NM_153366.4. SVEP1 protein reference sequence NP_699197.3. Variant allele
frequency data acquired from the Genome Aggregation Database (gnomAD, 2.1.1 release, 6 Mar 2019).
aNumber of times the variant allele has been observed versus the total number of alleles sequenced in the global population at that
genome position.
bNumber of times the variant allele has been observed versus the total number of alleles sequenced in an ethnically matched population
at that genome position.
predictions of pathogenicity, protein stability, and splice site
variation, as detailed in the Supplementary Materials. Candi-
date pathogenic variants were confirmed in the original DNA
samples by Sanger sequencing (see Supplementary Table S1
for primers), and segregation analysis was performed when-
ever familial DNA was available.
Exon Trapping: Functional Assessment of Splice
Site Variation
Exon trapping was performed as previously described.13,22
A 775 bp genomic fragment containing TEK exon 11 was
PCR amplified from the heterozygous proband of family 7.
Amplicons with and without the c.1624+5G>A variant were
sub-cloned into the pSPL3 exon trapping vector (Invitrogen
Life Technologies, Carlsbad, CA [discontinued]) using XhoI
and NdeI endonucleases (Life Technologies).
Functional Assessment of TEK Missense Variants
TEK missense variants were functionally assessed as previ-
ously described.13 Plasmids encoding TEK variants p.G136V,
p.V188G, p.Y193C, p.P244R, p.A841V, and p.G1035R were
created using site-directed mutagenesis. A plasmid encod-
ing TEK with a previously reported nonfunctional kinase
domain variant (p.D982A, kinase dead [KD]) was also used.13
Human Ocular Pathology
Enucleated globes were received in 10% neutral buffered
formalin and transferred to fresh neutral buffered formalin
for 48 hours before opening the eyes. Superior and inferior
calottes were removed and the remaining center sections
placed in tissue cassettes. Samples were processed through
an alcohol series and embedded in paraffin blocks. Sagit-
tal sections were cut, and select slides manually stained
with hematoxylin and eosin. All slides were imaged using
an Aperio ScanScope CS pathology slide scanner (Leica
Biosystems Inc., Buffalo Grove, IL) and Aperio ImageScope
software.
Localization of SVEP1 to Developing Mouse
Ocular Outflow Tissues
Mouse tissues were acquired following protocols that were
ethically reviewed and approved by the University of
Wisconsin–Madison School of Medicine and Public Health
Institutional Animal Care and Use Committee, and adhered
to the ARVO Statement for the Use of Animals in Ophthalmic
and Vision Research. Anterior segments from 1-week-old
wild-type (WT) mouse eyes were flat-mount immunos-
tained for SVEP1 and CD31 as detailed in the Supple-
mentary Materials. Briefly, enucleated eyes were immer-
sion fixed in 2% PFA, anterior eye cups dissected, and
tissues immunostained using rat anti-mouse CD31 antibody
(Cat # 553370, BD Pharmingen, San Jose, CA), rabbit anti-
human SVEP1 antibody (Cat # PA5-54436, Thermo Fisher
Scientific, Waltham, MA), goat anti-rat IgG Alexa Fluor
594 (Cat # A-11007, Thermo Fisher Scientific), and goat
anti-rabbit IgG Alexa Fluor 488 (Cat # ab150081, Abcam,
Cambridge, UK) secondary antibodies. Control tissues were
also processed without the addition of primary antibodies.
Eye cups were washed, flattened on glass coverslips, and
mounted with Shandon Immu-Mount (Thermo Fisher Scien-
tific). SC imaging was performed using a Nikon A1RS confo-
cal microscope.
The specificity of the anti-SVEP1 antibody was also veri-
fied via immunohistochemical staining sections of human
placenta (Supplementary Fig. S3).
Functional Assessment of SVEP1 Missense Variant
The SVEP1:p.R997C variant was functionally assessed as
detailed in the Supplementary Materials. Briefly, Svep1 cDNA
was amplified from mouse placenta and cloned into the
pSF-CMV-NEO-COOH-3XFLAG vector (Sigma-Aldrich Corp.,
St. Louis, MO). A SVEP1:p.R997C-expressing construct was
generated by site-directed mutagenesis. Constructs were
transfected into HEK293T cells (Thermo Fisher Scientific)
and SVEP1 detected by immunoblotting with anti-FLAG
M2 antibody (anti-GAPDH for loading control). Secreted
SVEP1 was detected in serum-free media after 2 days of
culture. Cell localization was studied 24 hours after transfec-
tion on glass cover slips using an anti-FLAG-FITC antibody
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(1:500; M2, F4049, Sigma-Aldrich Corp.), ProLong Diamond
antifade mountant with DAPI (Thermo Fisher Scientific), and
an Olympus BX51 fluorescence microscope.
The ability of extracellular SVEP1 to stimulate TEK
gene expression in human umbilical vascular endothe-
lial cells (HUVECs) (PCS-100-013; ATCC, Manassas, VA)
was assessed as follows: WT-SVEP1, p.R997C-SVEP1, and
empty FLAG vector were expressed by HEK293T cells in
vascular cell basal medium (VCBM; PCS-100-030; ATCC)
supplemented with Endothelial Cell Growth Kit-VEGF (PCS-
100-041; ATCC) for 2 days. Cell-free conditioned media
was collected, added to growing HUVECs for 24 hours,
the cells lysed and processed using a Cells-to-cDNA II
kit (Thermo Fisher Scientific), and quantitative real-time
PCR performed to assess TEK gene expression (TaqMan
probe Hs00176096_m1, FAM-MGB; Thermo Fisher Scien-
tific). Human ACTB endogenous control (FAM/MGB probe,
non-primer limited; Thermo Fisher Scientific) was used for
RNA normalization. Three independent experiments were
performed totaling 10 biological samples for each condition,
and four technical replicates averaged for each sample. TEK
expression in cells treated with WT- or p.R997C-SVEP1 was
calculated as fold change relative to untreated (empty FLAG
vector) cells using the 2−Ct method.23 Statistical signifi-
cance between the means of condition pairs were assessed
using the two-tailed t test. The standard deviation of each
condition was corrected to account for the three experiment
means used to pool the data.
RESULTS
Rare TEK Variants Identified in Eight PCG
Families
Exome sequencing identified eight PCG families with rare,
heterozygous variants in the TEK gene. The pedigrees for
these families are provided (Fig. 1), with ocular clinical
details (Table 1), gene variant information (Table 2), and
the protein location of each variant (Fig. 2). Nonocular clin-
ical features were noted in several members of family 8,
including ovarian cysts, Legg-Calvé-Perthes disease (osteo-
chondrosis of the hip joint), and gastroparesis (Supplemen-
tary Table S2).
All eight TEK variants were rare in the gnomAD
database, a compilation of exome/genome variants from
over 140,000 individuals. Six TEK variants were novel, and
two were each seen in only one individual (Table 2).
Because selection keeps deleterious gene variants at a
low population frequency, these rare TEK variants were
considered to be detrimental to the gene’s function. The
p.Y904* nonsense variant was located in exon 17 of the
23 exon gene, and expected to result in degradation of
the transcript via nonsense-mediated decay. The conse-
quence of the splice site variant (c.1624+5G>A) was
assessed in silico using Human Splicing Finder (HSF),
which predicted the donor splice site to be nonfunc-
tional. All six missense changes involved residues that
have been evolutionarily conserved for 360, 400, or
450 million years, since humans shared a common ances-
tor with the western clawed frog, coelacanth, or spotted
gar, respectively (see Supplementary Fig. S1). All affected
residues were located within important protein regions as
determined by crystallography (see Supplementary Fig. S2),
and all were predicted by in silico tools to impact protein
function and stability (Table 3). In addition, the p.G1035R
FIGURE 2. A diagrammatic representation of the TEK receptor
displaying the locations of 18 variants we have identified to date.
Eight variants identified in this study are highlighted in red, and 10
variants shown in black were previously reported.13 The receptor
contains three immunoglobulin-like domains (Ig1, Ig2, and Ig3) and
an epidermal growth factor-like domain (EGF) that are involved in
ligand binding, a fibronectin type-III domain (FNIII), a single-pass
transmembrane domain (cell membrane lipid bilayer represented
in green), and an interrupted protein kinase domain (TK) within
the intracellular C-terminal tail. The primary tyrosine phosphoryla-
tion sites, Tyr-1102 and Tyr-1108, are shown at the C-terminal tail,
which are responsible for initiating downstream signaling events.
TEK mRNA reference sequence: NM_000459.4. TEK protein refer-
ence sequence: NP_000450.2.
substitution resulted from a nucleotide change at the last
position of exon 20 (c.3103G>C, NM_000459.4), a location
important for donor splice site recognition. Analysis using
HSF, predicted the base change to result in a nonfunctional
splice site.
In all eight PCG families, no rare variants except for those
observed in TEK were identified in genes previously associ-
ated with PCG or later onset forms of glaucoma.
TEK Variants Represent LoF Alleles
In a cell-based exon trapping assay, the c.1624+5G>A splice
site variant destroyed the donor splice site, leading to skip-
ping of exon 11 (Fig. 3). TEK transcripts lacking exon
11 encode a receptor with an in-frame deletion of 45 amino
acids (Val497-Ile541, NP_000450.2) which form parts of
the immunoglobulin-like fold (Ig3) and fibronectin type III
(FNIII) domains. As these domains are integral for ligand
binding, we determine the splice variant allele to be LoF.
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FIGURE 3. Exon trapping of the TEK c.1624+5G>A donor splice site variant leads to skipping of exon 11. (a) Reference and variant mini-
genes were generated by incorporating genomic regions of TEK gene exon 11 into the pSPL3 exon trapping vector via XhoI and NdeI
restriction sites. Vector exons VE1 and VE2 are depicted as black boxes and TEK exon 11 is in gray. Reference (R) and variant (V) splicing
products are indicated by dashed lines above and below the construct, respectively. The location of the splice site variant is shown (*).
(b) Gel electrophoresis of RT-PCR products from transfected Cos-7 cells, using vector exon-specific primers (indicated by half-arrows in a).
pSPL3, cDNA template from cells transfected with empty pSPL3 vector only; No TF, cDNA template from cells transfected without plasmid
DNA. TEK mRNA reference sequence: NM_000459.4.
TEK receptors containing each of the six missense substi-
tutions were overexpressed in HEK293T cells and their solu-
bility levels, cellular localization, proteasomal degradation,
and functional activity were compared with WT receptors
(Fig. 4). TEK normally localizes to the plasma membrane,
and its tyrosine kinase activity can be detected via autophos-
phorylation of its C-terminal tyrosine residues. All six
missense variant receptors were unable to autophosphory-
late, similar to the KD mutant harboring a nonfunctional
kinase domain (Fig. 4). The six variant proteins also showed
lower expression intensities, suggesting instability or degra-
dation of the abnormal receptors. After 24 hours of MG132
proteasome inhibition, p.G136V-, p.V188G-, and p.A841V-
variant proteins were strongly detected in the insoluble frac-
tion, unlike their WT counterpart. In addition, immunofluo-
rescence microscopy showed that although WT-TEK local-
ized throughout the cytoplasm and plasma membrane, the
p.G136V mutant remained localized to a perinuclear cyto-
plasmic region, likely associated with proteasomes. These
findings demonstrated that all six missense variants resulted
in nonfunctional TEK receptors, and indicated the mutant
proteins are likely degraded via the proteasome pathway.
Altogether, the functional studies revealed that, along
with the nonsense change (p.Y904*), all eight TEK variant
alleles were LoF, further supporting receptor haploinsuffi-
ciency as a cause of PCG.
Ocular Pathology From Family 8 Revealed
Absence of Aqueous Outflow Structures
Histologic examination of the ocular outflow pathway was
possible for an affected member of family 8 (Fig. 1, family
8, individual IV-3, #), an 11-year-old with PCG refractory to
multiple surgeries. Comparison with an unrelated, disease-
free, 11-year-old eye was also possible owing to an enucle-
ation after a BB gun accident (Fig. 5). In the eye lacking
disease, and hematoxylin and eosin staining clearly revealed
the TM and SC, which was blood-filled owing to the injury.
In the affected eye, the anterior chamber showed a blunted
iridocorneal angle, with no evidence of TM or SC. Addition-
ally, the sclera was mildly hypercellular, and the scleral spur
was not evident. Descemet’s membrane did not end abruptly,
but showed an ambiguous tapering further into the angle to
a region where the TM should be located. To highlight SC,
tissue sections were immunostained for the EC marker CD31,
but no evidence of SC was observed in the PCG-affected
angle (data not shown).
Additional SVEP1 Variant Identified in Family 8
Exome sequencing 3 affected individuals (III-2, IV-2 and
IV-3) from family 8 identified additional rare variants in
the SVEP1 gene (p.R997C, rs761025824; Table 2) and nine
other genes (Supplementary Table S3). Sanger sequencing
confirmed the SVEP1 heterozygous missense change in four
of the five participating affected individuals, but it was
not carried by the youngest affected female (Fig. 1). The
other nine gene variants did not cosegregate with the glau-
coma phenotype. In gnomAD, the SVEP1-p.R997C variant
was observed in four alleles globally, and in silico anal-
yses predicted the substitution to be damaging (Table 3).
Comparative protein sequence alignments revealed conser-
vation of Arginine-997 over 450 million years, since
humans and spotted gar shared a common ancestor
(see Supplementary Fig. S1).
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FIGURE 4. Functional assessment of TEK missense protein expression, receptor activation, solubility, proteasomal degradation, and cell
localization. (a) WT and mutant TEK protein levels were detected by FLAG-tag immunoprecipitation and blotting (lower blot), while the
extent of receptor phosphorylation was detected with an antibody against phospho-tyrosine (pY, upper blot). Strong phospho-TEK levels
were detected with WT receptor, but all six mutant proteins failed to phosphorylate. (b) Left, G136V receptor levels were comparable to WT,
but phosphorylation was undetectable. Right, G136V protein showed increased insolubility that was more apparent following proteasome
inhibition. (c) Immunofluorescence microscopy detected WT receptors at the cell membrane and throughout the cytoplasm, but G136V
protein remained within a likely proteasome-associated cytoplasmic region. (d) Left, V188G receptors failed to autophosphorylate, similar
to the KD mutant. Right, V188G protein was detected at low levels, but identified as a strong insoluble component when proteasome
degradation was inhibited. (e) A841V receptors showed undetectable phosphorylation (left), and accumulation in the insoluble component
after proteasome inhibition (right). (f) G1035R receptors also failed to phosphorylate. IP, immunoprecipitation; IB, immunoblot; FLAG,
anti-FLAG; pY, anti-phosphotyrosine; TUB, anti-α-tubulin loading control; MG132, proteasome inhibitor; NT, not transfected; Sol., soluble
fraction; Ins., insoluble fraction; KD, TEK protein lacking kinase domain. TEK protein reference sequence: NP_000450.2.
FIGURE 5. Ocular pathology of iridocorneal angles from an age-matched control without ocular disease (a) and a PCG-affected individual
from family 8 (b). Histologic sections stained with hematoxylin and eosin. Note: SC is blood-filled in the control eye owing to physical
trauma. C, cornea; I, iris; TM, trabecular meshwork; SC, Schlemm 10s canal. Scale bar = 400 μm.
SVEP1 Is Expressed by Periocular Mesenchyme
Surrounding the Developing SC
Immunofluorescent confocal imaging of SVEP1 and CD31
expression in flat-mounted 1-week-old mouse anterior
segments identified the developing SC as an interwoven clus-
tering of branched vessels adjacent to the limbus (Fig. 6).
Strong SVEP1 staining was detected throughout the perioc-
ular mesenchyme and in close proximity to the ECs of the
maturing SC.
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FIGURE 6. Immunofluorescent confocal imaging of flat-mounted
1-week old mouse anterior segments stained for SVEP1 and
CD31 protein. (a) SVEP1 (green) expression is observed in the
mesenchyme of the developing iridocorneal angle. (b) CD31 (red),
an EC marker, is detected within the interwoven branches of the
maturing SC and the ancillary vasculature. (c) Overlay revealed
mesenchymal-expressed SVEP1 protein in close proximity to the
developing SC. (d) Anterior segments processed without the addi-
tion of SVEP1 and CD31 primary antibodies showed minimal back-
ground signal from the secondary antibodies alone.
SVEP1 Missense Variant Impairs Exogenous
Stimulation of Endothelial TEK Expression
Immunofluorescence microscopy of cultured HEK293T cells
expressing WT- and p.R997C-variant SVEP1 constructs
revealed comparable levels of protein localized to the
cytoplasm (Fig. 7A). Western blotting identified equiva-
lent levels of WT and variant SVEP1 in the conditioned
media, indicating both proteins were similarly secreted
(Fig. 7B). To evaluate the stimulatory effect of exoge-
nous SVEP1 on EC expression of TEK, HUVECs were
treated with SVEP1-conditioned medium and TEK expres-
sion measured by TaqMan assay. HUVECs treated with
WT-SVEP1 showed a moderate but consistent upregula-
tion of TEK expression compared with untreated cells
(1.29 fold change, P = 0.001; Fig. 7C and Dataset 1). In
contrast, p.R997C-SVEP1 treatment consistently failed to
enhance TEK expression (0.91 fold change, P = 0.139),
which revealed the p.R997C variant abrogated the exoge-
nous signaling function of SVEP1.
DISCUSSION
We report eight PCG families with rare heterozygous LoF
variants in the TEK gene, supporting a causative role for
TEK in PCG. More extensive pedigrees could be ascertained
for two families, which together contained ten individu-
als affected by PCG. Parent-to-child disease transmission
was observed in both families, providing strong evidence
in support of an autosomal dominant mode of inheritance.
TEK variants were also identified in several asymptomatic
individuals, an observation that is consistent with reduced
disease penetrance, and may be explained by the develop-
ment of variably hypomorphic SCs in carrier individuals, as
has been shown for hemizygous mice.13 Reduced penetrance
has also been reported for PCG caused by LoF variants in
CYP1B1.10,24–26 Notably, in a study of 22 Saudi kindreds,
40 asymptomatic individuals had CYP1B1 variants identi-
cal to their affected siblings.24 An analysis of the pedigrees
suggested the presence of a dominant modifier locus that
suppressed the disease phenotype.
Compared with the 17 other families identified with
functionally-confirmed TEK-related PCG, family 8 was
remarkable in several aspects. Their disease penetrance
was strikingly higher, with affected individuals observed in
five consecutive generations. Furthermore, 83% (5/6) of the
affected individuals presented with disease in both eyes,
whereas TEK-related PCG has been bilateral in 50% (10/20)
of the affected individuals identified to date. Additionally, the
disease in this family seemed to be more refractory to treat-
ment, with four individuals requiring enucleations despite
multiple attempts at surgical intervention to control IOP.
Histologic examination of one individual’s enucleated eye
(Fig. 1, family 8, individual IV-3, #) revealed an apparent
absence of SC and TM, comparable to murine eyes lacking a
functional Tek gene.13 Interestingly, a number of nonocular
clinical features were also noted in several family members
both with and without glaucoma, including four with ovar-
ian cysts, three with Legg-Calvé-Perthes disease, and two
suffering from gastroparesis. All five participating individ-
uals affected with PCG were heterozygous for a TEK LoF
variant, of which four had an additional rare variant in the
SVEP1 gene that was anticipated to be functionally deleteri-
ous. However, because the SVEP1 variant was not carried by
the youngest affected individual (V-3), it was not necessary
for PCG manifestation. Nonetheless, given the extraordinary
features of this family, we hypothesized that the SVEP1 vari-
ant could play a role as a disease modifier.
In zebrafish and mice, SVEP1 was found to be essen-
tial for lymphatic vessel formation.27,28 Zebrafish embryos
that lacked svep1 had aberrant venous sprouting and migra-
tion of lymphatic ECs (LECs).27 Similarly in mice, loss of
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FIGURE 7. Functional assessment of WT and p.R997C-SVEP1. (a) Immunostaining (green) of WT- or p.R997C-SVEP1 expressed in transfected
HEK293T cells. Nuclei are counterstained with DAPI (blue). (b) Immunoblot of conditioned medium from HEK293T cells expressing WT-
SVEP1, p.R997C-SVEP1, or an empty FLAG vector (EV). (c) TaqMan quantitative real-time PCR analysis showing fold change of TEK gene
expression in HUVECs treated with WT-SVEP1- or p.R997C-SVEP1-conditioned medium relative to untreated (empty FLAG vector) cells.
Error bars show the mean standard error over 10 samples per condition. Statistically significant differences between pairs of conditions are
denoted (*P < 0.05; n/s, not significant). SVEP1 protein reference sequence: NP_699197.3.
Svep1 caused abnormal lymphovenous connections and
lymphatic remodeling, which resulted in dysfunctional fluid
drainage and severe embryonic edema.27 During normal
development, SVEP1 is secreted from mesenchymal cells
and deposited around adjacent LECs, where it activates
lymphatic remodeling via forkhead box c2 (FOXC2) signal-
ing.28 Of relevance, dermal LECs isolated from mice lack-
ing SVEP1 showed reduced expression of Foxc2 and Tek,
implicating these genes as downstream effectors of SVEP1
signaling.28 Furthermore, other studies have shown that
FOXC2 can promote TEK expression in mouse and human
LECs.21 Together, these studies reveal that, during lymphatic
vessel development, SVEP1 acts as an extracellular signaling
messenger to stimulate FOXC2 expression in ECs, which in
turn upregulates expression of TEK.
In humans, we note that within the University of Washing-
ton’s shared web resource, Geno2MP (https://geno2mp.gs.
washington.edu/Geno2MP), exome sequencing has identi-
fied five additional SVEP1 missense variants in patients with
glaucoma (variant details provided in Supplementary Table
S4). All five alleles were rare and had CADD scores over
25, further supporting an association between SVEP1 gene
variants and glaucoma.
In consideration of these findings, we hypothesized that
the additional SVEP1:p.R997C variant in family 8 may act to
further decrease TEK receptor levels during SC development,
a specialized hybrid vessel that displays molecular markers
of both lymphatic and venous ECs. In mouse, SC begins
to form at birth when ECs sprout and migrate out from
blood vessels at the limbus, and by 1 week a rudimentary
vessel exists around the eye.6 During this period, the adja-
cent tissue of the future iridocorneal angle is composed of
a densely packed periocular mesenchyme.29,30 Immunoflu-
orescent imaging of 1-week-old mouse anterior segments
detected strong SVEP1 staining in the periocular mesenchy-
mal tissues surrounding the interwoven vessels of the devel-
oping SC, consistent with SVEP1 performing a similar role in
SC formation as has been shown for lymphatic development.
When HUVECs were grown in medium conditioned with
WT-SVEP1, a moderate but consistent upregulation of TEK
expression was stimulated, demonstrating exogenous SVEP1
can enhance vascular EC expression of TEK in this in vitro
system. In contrast, medium conditioned with p.R997C-
SVEP1 failed to promote TEK expression, confirming the
missense variant negated this aspect of the protein’s func-
tion.
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Together, the results suggest that the observed increase
in disease penetrance and severity in family 8 likely
resulted from limited TEK signaling within the develop-
ing SC. Consequently, these individuals would be expected
to show increased SC dysgenesis, which is consistent with
the observed ocular pathology. It should be noted that
several members of family 8 shared additional nonocular
clinical features, such as Perthes disease and ovarian cysts,
which may also be related to abnormal SVEP1 and/or TEK
signaling.
PCG is a devastating ocular disorder that affects infants
within the first 3 years of life. Although the initial ocular
hypertension is known to be caused by inadequate aque-
ous humor outflow, the underlying molecular and cellu-
lar disease mechanisms remain poorly understood. Herein,
we provide molecular genetic findings that support TEK
haploinsufficiency as a cause of PCG, and affirm the auto-
somal dominant inheritance pattern in two extended multi-
affected pedigrees. For the first time, we report evidence
underscoring a role for SVEP1 as a modifier of TEK expres-
sion in vascular ECs, and propose SVEP1 as a modi-
fier of TEK-related PCG disease penetrance and severity.
These findings provide a potential new molecular target for
directed therapeutic drug intervention in congenital glau-
coma.
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